Abstract
A clinical trial of Lidomex Kowa®lotion for inflammatory skin diseases was performed in the Department of Dermatology of Hokkaido University School of Medicine.
The efficacy and safety of topical 0.3% prednisolone 17-valerate 21-acetate preparations, Lidomex Kowa®lotion, were evaluated in 17 patients with atopic dermatitis and 3 patients with contact dermatitis.
The results showed at least moderate improvement in 80% of cases, especially with a better result in cases applied on the face and scalp.
No side effect was observed. Thus, the result demonstrated that Lidomex Kowa®lotion was safe, effective, preferable topical corticosteroid preparation.
